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terminologie. En in die derde plek is daar 'n soort tussen-
rigting wat die basie e intemasionale vorm nie vertaal nie,
maar verafrikaans. Op grond van hierdie drie skryfgebruike
sou dieselfde orgaan om die beurt byvoorbeeld a baar-
moedernek, cervix en erviks ge kryf kon word.
ou hoef die toestand soos hierbo geskets, niemand te
verontrus of te ontmoedig nie. Dit weer pieel nood aakIike
en onvermydelike aspekte van die organiese groei van 'n
joog en lewenskragtige taal. Maar, ons het nou tog 'n
stadium bereik waar versigtige en verstandige leiding, op
die basis van gedurige onderlinge bespreking en onder-
handeling, baie nodig geword het.
Vir ons wil dit dus voorkom of die volgende stap behoort
te wees om 'n raadplegende liggaam in die lewe te roep--
nie noodwendig met die doel om onrniddellike eenstemmig-
heid te probeer verkry nie-want dit sou skaars moontIik
wees, maar met die doel om langs die wee van gedurige
raadpleging en onderhandeling stap vir stap bereikte oor-
eenkomste te finaliseer en te boekstaaf.
So 'n raadplegende kommissie ou byvoorbeeld kon
bestaan uit mediese verteenwoordigers van die twee Afri-
kaanse mediese skote; 'n paar suiwer taalkundiges, in-
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sluitende verteenwoordigers van die S.A. Akademie vir
Wetenskap en Kuns, en van die personeel van die Afrikaanse
woordeboek; n paar ander raadgewers wie se liefde vir
die saak, en kwalifikasies, hulle geskik maak om as raad-
gewers in hierdie verband op te tree, en 'n verteenwoordiger
van die redaksionele personeel van die S.A. Tydskrif vir
Genee kunde. So'n kommissie sou wel kon, maar hoef
nie noodwendig, as geheel op gereelde tye te vergader nie.
Maar dit sou kon dien as 'n belangrike raadgewende lig-
gaam wat die organiese groei. van Afrikaans as mediese
vaktaal oor die loop van die volgende aantal jare in gesonde
kanale sou kon stuur.
Ons wil almal wat in hierdie saak belangstel, uitnooi om
daaroor te skryf en om wenke en raadgewing te stuur. Die
doel wat ons voor oe moet hou, is die geleidelike skepping
eo standaardiseriog van Afrikaans as mediese vaktaal sodat
die mediese studente wat deur die medium van Afrikaans
opgelei word, niks verloor nie, en sodat die mediese vak-
terminologie nog 'n faset kan word van die algemene kultuur-
bydrae van die Afrikaanse taal.
I. Redaksie (1944): s. Afr. T. Geneesk.. 18, 125.
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HAEMODY AMIC EFFECTS OF HYPOTENSIVE DRUGS A D CONSEQUE T
DANGERS IN THEIR USE*
B. GOLDBERG, M.D. (RA D!, M.R.C.P. (Lo D.) and 1. R. YUDAKE , M.B. (RAND), M.R.C.P. (EDIN.)
In recent years a considerable number of drugs have been
used in the treatment of hypertension. Their efficacy in
reducing the blood pressure varies with the drug or com-
bination of drugs used and from patient to patient. Their
ultimate effect on prognosis is not known but in a proportion
of patient considerable subjective relief is obtained during
treatment and in some an improvement in existing cardiac
and vascular di ease ensues. However, the lowering of
blood pressure may be accompanied by profound read-
justments in the circulation through- different organs or
parts of the body, which in some instances may result not
only in unpleasant and harmful but even lethal side effects.
A knowledge of the circulatory changes that do occur with
these drugs may permit one therefore to anticipate and so
perhaps avoid harm resulting from their use.
]n this paper some of the haemodynamic effect of the
ganglion-blocking agent, of reserpine, and of hydralazine,
are presented and discussed with particular reference to
tha heart and the renal and cerebral circulation. Difficulties
encountered in their use are illustrated with case reports,
and ome of the factors which should be considered in the
choice of drugs in the treatment of hyperten ive patients
are indicated.
Ganglion-Blocking AgenTS
Thi group consists of hexamethonium, pentapyrrolodi-
nium (pentolinium, Ansolysen) and mecamylamine (Meva-
sine) as well as several others. Their action in reducing the
blood pressure results from their effect in blocking transmis-
sion of impulses through autonomic (sympathetic) ganglia.
As far as is known, differences observed between the hypo-
tensive effects of the e "drugs are in the main due to the rate
* A paper presented at the South African Medical Congress,
Durban, September 1957.
and completeness of their absorption and excretion and
their duration 0 action. It has been suggested, however,
that the hypotension produced by mecamylamine may also
be a result of a central cerebral and direct cardiac effect.1
When administered parenter~lIy to hypertensive subjects
they cause a fall in blood pressure which is usually accom-
panied by a decrease in cardiac output or, in patients with
cardiac failure, by an increase; total peripheral resistan~e is
unchanged or reduced. 2 •4 In dogs, ventricular work and
coronary blood flow decrease. s The decrease in cardiac
output results from a reduction in venomotor tone with
an increa e in the capacity of the venous reservoir. 7 Venous
returh is reduced and the cardiac outpUt falls. With the
reduction in mean arterial pressure and hence coronary
filling pressure the coronary blood flow is decreased. Renal
blood flow and glomerular filtration rate fall but tend to
return within a short while towards control levels even
though the blood pressure remains lowered; renal vascular
resistance usually increases. 3 •6••9 These changes may tie
due to a reduction in cardiac output and a shift of blood
away from the splanchnic area to the periphery, where
vasodilatation occurs. In .both normal and hypertensive
individuals with no known cerebrovascular disease t.here
may be no change in cerebral blood flow with moderate
falls of blood pressure, or with more marked hypotens)on
the blood flow may be reduced. 10- 12 The decrease in cerebral
blood flow has been considered to be a passive one, resulting
from the decrease in blood pressure rather than from any
direct effect on the cerebral arteries.
Smith and Hoobler found that during maintenance therapy
with pentoliru'um a decrease in cardiac output without any
significant alteration in total peripheral resistance occurred,4
although during treatment with a combination of pentoLinium
jLiZ
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4.-year-old man had been ob erved during a 3-year period
during which his blood pres ure averaged 210 136 mm. Hg.
Because of the development of retinal and electrocardiographic
changes he was tarted on oral reserpin~ and pentolinium in
hospital. and was discharged with an a erage blood pres ure
in the recumbent po ition of about 165/113 mm. Hg. During
the next 3 months it became nece ary to increa e the thrice-a-day
dose of pentolinium from 75 mg. to 140 mg. and later to 180
mg. because of the development of tolerance to the drug. When
an attempt was then made to increase each dose by a further
20 mg. he developed faintness due to po tural hypotension and
substernal pain on excretion.
Fig. 2. The effect of intravenous hexamethonium on the
electrocardiogram of a hypertensive ubject. A: .Before
injection. B: 20 minutes after injection.
Fig. 3. The effect of intramuscular hydralazine on the digital
pulse .volume and blood flow of a hypertensive subject.
A: Basal. B, C. D, E and F: 15,30,45,60 and 70 minutes
after injection. The recordings on the left are at low paper
speed and how a mall pulse wave which does not increase
after injection. The recordings on the right at fast peed
show no ignificant alteration in the digilal blood flow
(measured by the teepness of the slope of the curvet unit
time).
Fig. 2 illustrates ischaemic electrocardiograpbic change
after the intravenou injection of he amethonium ID a
hypertensive patient.
Hydralazine
Hydralazine (Apresoline, I-hydrazinophthalazine) ha
been shown to be an effective hypotensive agent acting, both
centrally on the brain (possibly the hypothalamus) and
peripherally on the arterioles so a~ to produce va odilatation
and thereby the blood pressure. 15 The injection of hydrala-
zine produces a sympathomimetic effect on the heart,
with an increase in heart rate, stroke volume and cardiac
output. Vasodilatation occur, particularly in the splanchnic








Fig. I. The effects of treatment with a combination of oral
reserpine and mecamylamine on the renal circulation of a
hypertensive patient. GFR=gJomerular filtration rate.
. RPF=renal plasma flow. FF=filtration fraction (GFR/
RPF}. RVR=renal'vascular resistance (ratio mean blood
pressure/renal blood flow). umbers on top of columns
are absolute values.
and reserpine no consistent alteration in cardiac outptu
was noted. '3 The reduction in blood pressure occurring
during treatment has been attributed to this change in
'cardiac output rather than to any alteratio/1. in the peri-
pheral resistance. Maintenance therapy with hexametho-
nium or a combination of ganglion-blocking drug and
reserpine does not result in any marked changes in the
renal circulation of recumbent hypertensive patients (Fig. I)
except for a decrease in renal vascular resistance and a slight
reduction in glomerular filtration rate. '3 ."
Based on these observations one might expect that renal
insufficiency may occur or, when previously present, be
aggravated by treatment with a ganglion-blocking drug.
That this is so is supported by reports of the development of
increasing and fatal uraemia during treatment. 15 . 16 How-
ever, provided renal functional impairment is not too severe
and a gradual reduction in blood pressure is achieved,
with care these drugs can be used. 13 ,17,IS
SiQ1ilarly in 'the presence of cerebrovascular disease a
reduction in blood pressure may be accompanied by un-
desirable side-effects due to cerebral ischaemia, as illus-
trated in the following case report:
A 68-year-old man was readmitted to hospital 10 weeks
after a previous admission for myocardial infarction. He had
had a cerebral thrombosis 18 months previously. On the day
of admission he took for the first time some pentolinium pills
which had been prescribed for hypertension. An hour or two
later he felt faint and collapsed, and on recovering consciousness
found his right side to be paralyzed. Examination showed a
hemiparesis, blood pressure was 160/90 mm. Hg, and his pupils
were widely dilated. During the next few hours the blood pressure
gradually rose and eventually averaged 208/123 mm. Hg. Parallel
with the rise in blood pressure there was a progressive recovery
from the hemiparesis.
Although cardiac output and ventricular work are reduced
by ganglion-blocking drugs the coronary blood flow also
decreases. This reduction, if proportionately greater than
the decrease in ventricular work, may result in myocardiaI
i chaemia.













TABLE 1. SUMMARY OF THE EFFECTS OF GANGUO BLOCKING DRUGS,









+ = increase. - = decrease. 0 = no change. . ? = effect
doubtful.
thonium alone.a The increase in the heart rate following
the administration of hydral~e is prevented if reserpine
is also given.25 It is possible that the action of the ganglion-
blocking agents on the cardiac output may be antago,nistic
to the opposite effect of hydralazine, although hexame-
thonium does not inhibit the renal vasodilating action of
hydralazine.26 In Table I are summarized the various fiae- .
modynamic alterations produced by the individual drugs.
DISCUSSION
The heart, kidneys and brain are the important organs
which may suffer harm from the hllemodynamic changes
that occur during treatment with hypotensive agents. The
patient who will suffer and the part which will be affected
will depend upon the particular drug used and the presence
and severity of accompanying vascular disease.
A reduction in blood pressure resulting from the use
of ganglion blockers' may result in a decreased cerebra-!.
blood flow. When cerebro-vascular disease is present,
not in the form 'of hypertensive encephalopathy, but in
the fonn of associated organic cerebral arterial disease,
this reduction in blood flow may result in general or local
cerebral ischaemia and anoxia. While we have not observed
cerebral is~haemia during treatment with hydralazine or
reserpine we have seen syncope follow a single ~jection of
hydralazine. In the elderly atherosclerotic hypertensive
patient it is likely that a sudden, marked reduction in syste-
mic blood pressure, produced by any means, will result
in cerebral ischaemia and its sequelae. It follows, therefore,
that in this type of patient hypotensive treatment should
be instituted cautiously and only when the disease' itself
is of sufficient severity to warrant treatment. The aim of
therapy is to produce a moderate and gradual lowering of
the blood pressure, avoiding sudden sharp reductions.
Thereby one may alleviate the symptoms, and perhaps
prevent the progression, of the generalized hypertensive
vascular disease. The gradual and moderate reduction in
pressure that is desirable is characteristic of the action of
reserpine, which is the drug of choice in these cases. Treat-
ment with reserpine alone, however, is not always adequate,
and then the addition of h:(dralazine in gradually incre~ing
doses may be effective. Moreover, the postural hypotension
which occurs during maintenance treatment with the gan-
glion-blocking agents is not a problem with reserpine and
hydralazine.
In the presence of severe progressiv~ renal functional
impairment it is unlikely that the reduction in bloo<l'pressure
will prevent the usual fatal outcome. However there is
little doubt that associated hypertension worsens the prog-
I
renaJ blood flow increases but the glomerular filtration rate
i unchanged and the filtration fraction consequently
falls.6 ,lD,21 The digital blood flow may increase or not
alter20 ,21 (Fig. 3). The cerebral blood flow remains constant
in spite of the decrease in blood pressure and the cerebral
vascular resistance decreases.22
During 'maintenance therapy with hydralazine the mean
r~sting renal plasma' flow is usually not altered significantly,
although in individual patients a moderate increase has been
noted. Moreover, after a period of treatment oral administra-
tion of hydralazine fails to increase the flow significantly,
indicating the development of tolerance to the drug.23
The effect of hydralazine in increasing ventricular work
may be manifest clinically as coronary insufficiency or
cardiac failure.
A 50-year-old man had a thoraco-Iumbar splanchnicectomy
in 1949 because of malignant hypertension. Two years later
his blood pressure was about 250/150. mm. Hg and he had symp-
toms and signs of cardiac failure. He was treated with digitalis,
diuretics and for a while with hexamethonium; cardiac failure
improved and the blood pressure was reduced moderately. In
April 1952 hydralazine was given. On taking 50 mg. t.i.d. he
experienced for the first time pain in his jaw. On reducing to
25 mg. t.i.d. this pain was not felt, but symptoms of cardiac failure
returned, with breathlessness and oedema of the legs. This was
controlled again with diuretics and hydralazine was stopped
for a week. When it was resumed in a dose of 50 mg. t.i.d. he
had anginal pain 'about 45 minutes after the second and
also the third dose. Hydralazine was again stopped for one
day. On resumption pain occurred in the chest, jaw and
arms, with palpitations. Ther<:after the dose wai reduced to
25 mg. t.i.d. with no angina but also no significant change in the
blood pressure. Hypoten ive treatment was stopped for 4 months
but when hydralazine was started. again angina recurred.
Subsequently he was treated with reserpin~ and hydralazine
with a good effect on blood pressure but with the development
of severe mental depression. '
Reserpine
The mode of action of the rauwolfia alkaloids, of which
reserpine is one, appears to be a centrally mediated (possibly
hypothalamic) .depression of sympathetic nervous activity
with resulting peripheral vasodilatation and consequent
reduction in blood pressure.24
In acute experiments on dogs ana in hypertensive patients
the intravenous administration of reserpine causes no con-
sistent effect on cardiac output and the fall in blood pressure
has been shown to be due to a decrease in peripheral re-
sistance. Similarly no consistent alteration in the glomerular
filtration rate or renal blood flow has been observed.24
During maintenance therapy with reserpine alone or a
combination of reserpine and pentolinium no significant
change occurs in the renal plasma flow or glomerular filtra-
tion rate.. The renal vascular resistance decreases.9•13 ,24
We have observed no deleterious effects due to haemody-
namic changes in patients treated with reserpine alone.
Combination 0/ Drugs
Since many patients are treated with combinations of the
various hypotensive drugs it' is of importance to know
whether the action of one is modified by simultaneous
treatment with another. It has been shown that pre-treat-
ment with reserpine does not prevent the acute renal hae-
modynamic changes produced by hexamethonium.9 Simi-
larly, the effects on renal haemodynamics of maintenance
therapy with a combination of reserpine and pentolinium13
are similar to those reported during treatment with hexarne-
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nosis of renal disease, either directly by its effect on the
ki~ey's, or secondarily b.y the production of cardiac failure.
It IS Important, therefore, in these instances to try and
reduce the bl<;>od -pressure and so retard these changes.
When renal dl~~, although advanced, is static or only
sl.owly progressIve It may be possible by treatment to alle-
vIate s~ptoms due. to hy.pertension and perhaps improve
prognoSIS. TheoretJcally the drug of choice under these
~ir~ums~ces should be hydralazine, by virtue of its effect
m mcreasmg blood flow. We have observed in an occasional
~ndivid~l with severe but only slowly progressive renal
msuffiClency an apparent improvement in renal function as
evidenced by a gradual decrease in the blood urea over a
period of months. Howev~r, this is unusual and, because it
has been shown that hydralazine does not significantly
affect renal blood flow during maintenance therapy, the
~~st that can J:>e hoped for in the majority of these cases
JS that by reducmg the blood pressure the incidence of other
fatal consequences of, hypertension, particularly cerebral
h~etporrhage 'and cardiac failure, will be lessened. While
hydralazine is the drug of choice when renal disease is
,severe, it has t>.een shown that the ganglion-blocking agents
can be used WIth care and combined with hydralazine and
r~rpine in the treatment of these cases. As with patients
WJth cerebro-vascular disease the aim of treatment is to
produce a gradual decrease in blood pressure. However,
as, the ~anglion-blocking agents are excreted in the urine,
cumulative effects of these drugs may occur unless incre-
ments in'dosage are small and made slowly. If this is not
done, acute hypotension may result, with rapid worsening
of renal function due to a decrease in the glomerular filtra-
tion rate. Irr general it is safe to use the ganglion-blocking
agen.~s ~ the blood urea is less than 70 mg. % provided
cautIOn IS exercised and renal function is' checked fairly
frequently, particularly by the blood urea. The aim of
treatment is to reduce the blood pressure to a level which
is not associated with increasing uraemia. If the blood urea
does. rise it is iser to allow the pressure to increase slightly
by a reduction in the dose or by temporarily stopping the
administration of the drug.
We have illustrated the development of angina during
treatment with pentolinium; but .this is unusual and in
the majority of inst~nces the ganglion-blocking agents are
the drugs of choice in the treatment of hypertension with
associated myocardial or coronary-artery disease. Often
symptoms of cardiac failure are improved, as in angina.
This results from the decrease in cardiac work. Hydralazine,
on the other hand, may increase the severity o( the symptoms
of coronary insufficiency, or in some instances, as shown,
produce them for the first time. It is best to avoid its use in
patients with cardiac involvement or to combine it with
reserpine or a ganglion-blocking drug if treatment is in-
adequate without it. The antagonistic effect of reserpine
on the tachycardia, and of the ganglion-blocking agents on
the mcrease in cardiac output, produced by hydralazine
may prevent or reduce the incidence of side-effects.
No attempt has. been made here to discuss the other
The South African Society of Obstetrics and Gynaecologists (Cape
Town branch). At the annual general meeting of this society
held on 2 June 1958 at Medical School, University of Cape Town,
toxic effects of the hypoten ive drugs. Treatment may be
difficult because of the parasympattietic blockade resulting
from the use of ganglion blockers with consequent genito-
urinary, ga tro-inte tinal and vi ual di turbances. With
hydralazine the production of the drug ra h, fever, blood
dyscrasia or a collagen-like disease may interfere with
treatment. When reserpine is u ed, in addition to the lesser
toxic effects marked mental depression may be produced
which may make it necessary to stop the drug. The efficacy
of the various drugs in their hypotensive action, and the ease
with which control of blood pressure is achieved with a -
particular drug in in-patients and out-patients has not "been
discussed. Only the haemodynamic effects have been pre-
sented and, although not common, in some patients these
changes result in unpleasant symptoms and even harm.
It is hoped, however, that a knowledge of the factor di-
cussed will make the treatment of hypertension iQ the indi-
vidual patient afer and control easier.
SUMMARY
The haemodynamic effects of a group of hypotensive drugs
are discussed with special reference to their effects on the
heart and the renal and cerebral circulations. The effect
observed in hypertensive subjects of the ganglion-blocking
agents and reserpine on the kidney and of hydralazine on
the heart are presented and compared. Reference is al 0
made to their effects on the cerebral circulation.
On the basis of these findings possible dangers in the use
of these agents in the treatment of hyperten ion are pointed
out and illustrated with case reports. Indications and contra-
indications for the use of particular drug or combination
of drugs in individual patients are di cussed.
We are indebted to Dr. M. M. Suzman for permission to study
patients under his care and to Prof. H. B. Stein, Department of
Clinical Pathology, for providing laboratory facilities.
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